References
- Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford University Press; 2005.
- Eandi M, Pradelli L, Zaniolo O. Farmacoeconomia. Principi di base. SEEd, 2005.
- Roggeri D. Le basi della farmacoeconomia. Corso di farmacoeconomia per neonatologi. Roma Maggio 2007.
- Nuijten MJ, Wittemberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics, 2007; 25(1):55–71.
- Harkensee C, Brodlie M, Embleton ND, Mckean M. Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect. 2006; 52(1):2–8,Epub 2005 Oct 19.
- Lofland JH, Touch SM, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Therapeut 2000; 22, 11: 1357–1369.